Erdoğan Özdemir

Dr. Erdoğan Özdemir

Internal Medicine, Elazığ Fethi Sekin City Hospital, Elazığ, Turkey (Türkiye)
orcid
Internal Medicine Specialist

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EÖErman Özdemir
Erman Özdemir
PÖPINAR ÖZDEMİR
PINAR ÖZDEMİR
SYSerap Yadigar
Serap Yadigar
SYSerkan Yalin
Serkan Yalin
EPErgün Parmaksız
Ergün Parmaksız
MAMehmet Riza Altiparmak
Mehmet Riza Altiparmak
Background: Acute phosphate nephropathy (APN) is an underrecognized cause of acute kidney injury (AKI), typically associated with the use of oral sodium phosphate (OSP)-based bowel preparations. It is characterized by calcium phosphate crystal deposition within the renal tubules and may result in permanent renal impairment. Despite known risks, phosphate-containing solutions are still widely used without sufficient risk stratification. Methods: We retrospectively evaluated 517 native kidney biopsies performed in our nephrology clinic between 2017 and 2022. Among these, 12 patients with unexplained AKI and recent colonoscopy history were identified. In nine cases, non-specific tubular deposits on routine staining prompted further histochemical analysis. All had a history of recent OSP-based bowel cleansing. The use of von Kossa staining confirmed calcium phosphate deposition, consistent with APN. Results: Out of 517 kidney biopsies performed during the study period, 9 patients were diagnosed with APN based on histopathological findings following recent colonoscopy and OSP-based bowel cleansing. The mean age was 58.7 years, and three were female. Hypertension was present in seven patients, diabetes mellitus in three, and epilepsy in two; one patient had no comorbidities. Baseline renal function was normal (mean serum creatinine 0.86 mg/dL) and increased to 1.76 mg/dL at three months post-exposure. All biopsies revealed tubulointerstitial calcium phosphate deposits and interstitial inflammation; mesangial hypercellularity was observed in five cases, tubular atrophy in three, and acute tubular necrosis in one. All samples stained positive with von Kossa staining. Over time, all patients developed chronic kidney disease, and one progressed to end-stage renal disease requiring dialysis. Conclusions: In patients presenting with unexplained AKI and recent OSP-based bowel preparation, APN should be considered in the differential diagnosis. When routine histology is inconclusive, definitive diagnosis may require special histochemical staining. Risk-based restrictions on phosphate-containing agents are warranted to reduce preventable kidney injury.

13 June 2026 in Acta Medica Nicomedia
Verified
Journal Article
Closed access
EÖErman Özdemir
Erman Özdemir
Erdoğan ÖzdemirErdoğan Özdemir
Erdoğan Özdemir
SYSerap Yadigar
Serap Yadigar
PÖPINAR ÖZDEMİR
PINAR ÖZDEMİR
Objective: Rheumatoid arthritis (RA) is a systemic autoimmune disorder marked by chronic inflammation, with considerable heterogeneity in both disease trajectory and therapeutic response. The objective of this study is to assess whether RF and anti-CCP antibodies can serve as predictive markers for treatment outcomes in patients with rheumatoid arthritis undergoing anti-TNF-α therapy. Methods: This retrospective study analyzed 80 RA patients undergoing anti-TNF-α therapy (adalimumab, infliximab, or etanercept), stratified by serologic status: RF-positive alone (n = 27), anti-CCP-positive alone (n = 27), and double-seronegative (n = 26). Comprehensive disease activity assessment was performed using DAS28 scores, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels at baseline and following 12 months of treatment. Results: All groups showed significant improvement in ESR, CRP, and DAS28 scores after 12 months (p=0.001). No significant differences were observed between the groups in treatment response (p=0.587 for ESR, p=0.767 for CRP, p=0.999 for DAS28). Conclusion: RF and anti-CCP positivity did not significantly influence treatment response to anti-TNF therapy. Further studies with larger cohorts and quantitative antibody measurements are needed to confirm these findings.

7 September 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
Erdoğan ÖzdemirErdoğan Özdemir
Erdoğan Özdemir
FGFatih Genç
Fatih Genç
TYTurgay Yılmaz
Turgay Yılmaz
DDDeccane Düzenci
Deccane Düzenci
Background: Phoenixin-14 (PNX-14) is a bioactive peptide associated with mitochondrial function, oxidative stress responses, and cellular protection. Although experimental data suggest a possible role in renal injury, its serum levels in chronic kidney disease (CKD) have not been previously studied. Given the limitations of conventional renal biomarkers, PNX-14 may offer additional information regarding renal dysfunction in CKD. Methods: This single-center, prospective, observational, cross-sectional study included 140 adult patients with Stage 3 CKD ( n = 30), Stage 4 CKD ( n = 30), Stage 5 CKD ( n = 30), and end-stage kidney disease receiving maintenance hemodialysis (HD) ( n = 50). Serum PNX-14 was measured using a commercial ELISA kit, before and after dialysis in HD patients. Associations between PNX-14 and clinical and laboratory parameters were assessed using Spearman correlation. Receiver operating characteristic (ROC) curve analysis evaluated the discriminative performance of PNX-14 across CKD stages. Results: Serum PNX-14 levels increased progressively with advancing CKD stage, from a median of 17.88 (IQR 15.16–20.20) pg/mL in Stage 3–43.14 (IQR 23.78–95.71) pg/mL in the HD group ( p < 0.001). Post hoc analysis showed that PNX-14 levels were significantly lower in Stage 3 than in Stage 5 and HD, in Stage 4 than in HD, and in Stage 5 than in HD. PNX-14 showed significant positive correlations with creatinine and parathyroid hormone (PTH) and a significant negative correlation with eGFR (all p < 0.001). In the pre-dialysis subgroup, PNX-14 remained significantly correlated with creatinine, eGFR, urea, and PTH. In HD patients, no significant difference was observed between pre-dialysis and post-dialysis PNX-14 levels ( p = 0.152), and no significant correlation was found between PNX-14 and Kt/V. ROC analysis demonstrated good discriminative performance for distinguishing Stage 3 from advanced disease (Stage 5 + HD), with an AUC of 0.839 (95% CI: 0.755–0.913). The optimal cut-off was 19.59 pg/mL, with 87.5% sensitivity and 73.3% specificity. Conclusions: Serum PNX-14 levels increase with worsening CKD stage and are strongly associated with renal function parameters. Its limited change after HD and its discriminative performance suggest that PNX-14 may provide clinically relevant information regarding disease severity in CKD. Further prospective and longitudinal studies are needed to clarify its potential clinical utility.

30 September 2026 in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
Verified
Journal Article
Closed access
EÖErman Özdemir
Erman Özdemir
Erdoğan ÖzdemirErdoğan Özdemir
Erdoğan Özdemir
PÖPINAR ÖZDEMİR
PINAR ÖZDEMİR
Objective: Synthetic cannabinoid-associated acute kidney injury (SC-AKI) is difficult to recognize because routine toxicology may not detect emerging compounds and exposure may initially be undisclosed. We evaluated whether metabolic alkalosis and microscopic hematuria identify a distinct clinical pattern among young adults with severe AKI.Methods: This single-center retrospective frequency-matched study included patients aged 18-45 years with KDIGO stage 3 AKI evaluated between January 2016 and December 2023. Eleven patients with probable SC-AKI were compared with 44 non-SC AKI controls matched by sex, age distribution, admission creatinine, and peak creatinine. Fisher exact and Mann-Whitney U tests were used.Results: Median age was 34 versus 35 years and admission creatinine was 5.9 versus 6.25 mg/dL. Metabolic alkalosis occurred in 7/11 SC-AKI patients and 5/44 controls (p

15 May 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
Erdoğan ÖzdemirErdoğan Özdemir
Erdoğan Özdemir
TYTurgay Yılmaz
Turgay Yılmaz
Background and aim: Liver enzyme elevations between one and two times the upper limit of normal (ULN) are common in outpatient practice and often dismissed as clinically insignificant, yet whether this range harbours meaningful subphenotypes, and whether the hepatocellular–cholestatic distinction applies at borderline levels, has not been systematically examined. We investigated whether, in adult outpatients with persistent borderline elevation confirmed using sex-specific ULN, the hepatocellular and cholestatic patterns carry distinct metabolic and inflammatory signatures. Materials and methods: This single-centre observational outpatient study was conducted at Elazığ Fethi Sekin City Hospital between October 2024 and January 2026. Eight hundred adults with standardised fasting biochemistry and haematology panels at baseline and third-month follow-up were analysed. Liver enzymes were classified as normal, borderline, or overtly elevated by the maximum fold-increase above the sex-specific ULN; borderline cases were subcategorised as hepatocellular, cholestatic, or overlap. Clinical, biochemical, inflammatory, and iron parameters were compared, and independent associations were examined using multivariable logistic regression. Results: Enzyme levels were normal in 548 patients (68.5%), borderline in 211 (26.4%), and overtly elevated in 41 (5.1%). Among the 211 borderline patients, 105 (49.8%) exhibited a hepatocellular pattern, 77 (36.5%) a cholestatic pattern, and 29 (13.7%) an overlap pattern. The hepatocellular pattern was associated with higher ferritin, serum iron, and transferrin saturation (TSAT), and a lower AST/ALT ratio; in multivariable analysis, ferritin was the only independent correlate (OR = 1.523; 95% CI: 1.199–1.935; p = 0.001). The cholestatic pattern showed higher HbA1c, higher systemic immune-inflammation index (SII), and lower TSAT; the independent predictors were HbA1c (OR = 1.591; 95% CI: 1.168–2.168; p = 0.003), SII (OR = 2.205; 95% CI: 1.228–3.960; p = 0.008), and TSAT (OR = 0.679; 95% CI: 0.489–0.943; p = 0.021), preserved in the non-diabetic subgroup. The overlap pattern exhibited features of both pure patterns. Conclusion: Persistent borderline liver enzyme elevation can be stratified into biochemically distinct subphenotypes when sex-specific reference ranges are applied. The cholestatic pattern is predominantly associated with glycaemic burden, systemic inflammation, and reduced iron transport, whereas the hepatocellular pattern shows an iron-predominant signature. A pattern-based approach may carry clinical value in outpatient management; findings from full models with limited events-per-variable, particularly for SII, are hypothesis-generating and require longitudinal validation.

21 July 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Erdoğan ÖzdemirErdoğan Özdemir
Erdoğan Özdemir
TYTurgay Yılmaz
Turgay Yılmaz
DDDeccane Düzenci
Deccane Düzenci
Background: Albumin-adjusted calcium is widely used despite uncertainty about its accuracy in critically ill adults. We prospectively evaluated the diagnostic performance of total calcium and of multiple published albumin-correction formulae against ionised calcium, the physiological reference standard, in an intensive care unit (ICU) cohort. Methods: In this prospective observational cohort study, ionised calcium (iCa), total calcium, albumin, venous pH, creatinine, estimated glomerular filtration rate (eGFR), C-reactive protein (CRP), procalcitonin, magnesium, phosphate and vitamin D were measured simultaneously. The primary outcome was the diagnostic accuracy (area under the ROC curve [AUC]; sensitivity/specificity) of total calcium and of corrected calcium for detecting hypocalcaemia, defined a priori by the reference standard as iCa < 1.12 mmol/L; the pre-specified contrast was the difference between the two correlated AUCs. Twelve published measures were compared (total calcium; Payne; simplified Payne; Orrell; Berry; James; Jain; Thode; and the Pekar and Antonio estimators). Agreement, formal subgroup interaction tests, an explanatory multivariable model with collinearity diagnostics, and an exploratory internally-validated ICU equation were assessed. Results: In total, 250 patients were enrolled (median age 70 years; 147 men, 58.8%). Hypocalcaemia prevalence was 58.0% (n = 145). Payne-corrected calcium correctly identified only 15.2% of truly hypocalcaemic patients (Cohen κ = 0.08), versus 62.8% for total calcium (κ = 0.40). No simple albumin-correction formula significantly outperformed unadjusted total calcium (AUC 0.69–0.75; all DeLong p > 0.05 vs total calcium AUC 0.74). Only the four-variable Pekar estimator achieved a higher AUC (0.78; p = 0.005). In the explanatory model, only total calcium, pH, and sex independently predicted iCa (all variance inflation factors < 1.8); albumin, phosphate and vitamin D were not significant. An exploratory ICU-specific equation reached an optimism-corrected R² of only 0.17. Conclusions: Albumin-corrected calcium, including all established formulae tested, provides no diagnostic benefit over total calcium in the ICU and frequently masks true hypocalcaemia. Direct ionised-calcium measurement should be prioritised when accurate calcium status affects management. These are diagnostic-accuracy findings; their clinical-outcome implications require outcome-anchored study.